MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
25. Juni 2023 09:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report...